WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Comparing Breast Cancer Clinical Trials: Regulatory Approaches in the United Sates and India

Sonali B. Khedkar

Modern Law College,Pune

ABSTRACT

Breast cancer remains a significant global health concern, hence, there is need to continue developing new treatments through research and clinical trials. Regulatory frameworks determine how clinical trials are designed and conducted in different countries. The article compares the regulatory requirements for conducting clinical trials on breast cancer in the United States and India. In the U.S., the Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP) enforce a thorough regulatory process with detailed approval procedures, ethical guidelines, and phased trial stages. The FDA's expedited pathways and safety protocols aim to protect participants and ensure reliable results. In India, the Central Drugs Standard Control Organisation (CDSCO) and the Indian Council of Medical Research (ICMR) oversee trials with a regulatory structure of its own healthcare context. Regulations in India have been evolving to present streamlined clearance and heightened ethical standards while confronting regional issues. This paper compares the two countries' approval processes, ethics considerations, and recent regulatory changes. Understanding these regulatory landscapes is crucial for international researchers and sponsors, as it impacts the speed and quality of breast cancer research, ultimately contributing to better treatment options and patient care worldwide.

Key words: Breast cancer, clinical trials,

Introduction

Probably one of the most common and dangerous forms of cancers in women, breast cancer necessitates the detection of new, more promising treatments. , and clinical trials play a key role in this process which test a new drug, therapy, or technology for safety and effectiveness before they can be released for more widespread use among patients.

However, rules and regulations regarding clinical trials can vary from country to country. These regulations affect all parts of the trial process, from how studies are designed and conducted to how participants are recruited and how results are reported. Understanding these regulations is particularly important for researchers and companies developing new treatments, as it can influence how quickly these new treatments are available and the quality of the research.

In the United States, clinical trials are governed by various important organizations: for example, the Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP). In an effort to systematically develop the framework through which these agencies ensure that the trials are undertaken ethically and that any new treatments proved are safe and effective, the United States has a system well put in place.

India also has its own regulatory system for clinical trials, primarily coordinated by the Central Drugs Standard Control Organization (CDSCO) and the Indian Council of Medical Research (ICMR). India is still improving in its regulations and so remains developing. The regulations in India are adapted to its unique population and healthcare challenges, which can work in favor of research but this very same reason complicates it simultaneously.

This article will compare the regulatory requirements for breast cancer clinical trials in the United States and India. We will look at how each country's approval processes, ethical standards, and recent changes impact the trials. By understanding these differences, researchers and sponsors can better navigate the international landscape of clinical trials and contribute to the global effort to improve breast cancer treatments.

Regulatory Bodies

United States

FDA (Food and Drug Administration):

The FDA is one of the primary U.S. agencies that regulates clinical trials of all health conditions, of which breast cancer is included. Its core objective is to ensure that new drugs and treatments are safe and effective enough to be marketed to the public. The FDA has strict regulations dictating every phase, from planning up to follow-up after the clinical trial.

IND Application: The firm should file for an Investigational New Drug (IND) application with the FDA before proceeding with the clinical trial. This will consist of the data obtained earlier from preliminary tests, a detailed plan for conducting the clinical trial, and information about how the drug is manufactured. The FDA then makes a decision regarding whether the trial can be performed safely and to determine if the trial is safe and if the drug has potential benefits.

Phased Trials: Clinical trials in the U.S. are done in phases:

Phase I:Tests the drug's safety on a small group of people. Phase II: Checks how well the drug works on a larger group.

Phase III: Confirms the drug's effectiveness and watches for side effects in an even larger group.

Ethical Oversight: The FDA oversees trials with high ethical standards. This entails that participants be thoroughly informed about what the trial entails and give permission before participating. In case serious issues arise, the FDA monitors these trials and can withdraw themto prevent harm to the participants.It helps to guarantee that innovative treatments are tested and hence safe for use before being dispensed to patients.[1]

India

CDSCO(Central Drugs Standard Control Organization)[2]

The CDSCO is the primary agency responsible for drug regulation and the overall conduct of clinical trials in India. Before a clinical trial can be initiated, a company needs to submit a Clinical Trial Application(CTA) to the CDSCO. Details about the drug and its testing are included in the Clinical Trial Application. CDSCO looks at this information for safe conduct of the trial and regulatory compliance.

CDSCO monitors the ongoing trials to ensure that these are conducted in an appropriate manner and also ensure the protection of the participants. Further, they ensure that the participants provide their informed consent.meaning they fully understand what the trial involves, and that the results are reported openly.

ICMR (Indian Council of Medical Research):

The ICMR plays a key role in guiding and overseeing medical research in India. They set rules to make sure that research is done ethically, including ensuring that participants are fully informed about what they're agreeing to and that their rights are safeguarded. The ICMR also works to enhance the quality of research and ensure that trials meet both national and international standards.

Understanding how CDSCO and ICMR operate helps researchers and companies navigate the regulatory landscape for clinical trials in India. This ensures that trials are conducted safely and ethically, leading to better treatments and improved patient outcomes[3].

Approval Processes for Clinical Trials United States:

IND Application: Before starting a clinical trial, a company or sponsor must submit an

Investigational New Drug (IND) application to the FDA. This application includes important details such as results from earlier tests, a detailed plan for the trial, and how the drug is made. The FDA reviews this application to determine if the trial is worth pursuing, balancing the potential benefits against any risks.

IRB Approval: An Independent Review Board (IRB) must review and approve the trial plan to ensure it meets ethical standards. The IRB looks at things like how the risks to participants are managed, how informed consent is handled, and the overall design of the study to ensure it is ethical and fair.

Phased Clinical Trials: Clinical trials in the U.S. are divided into phases:

Phase I:Tests the safety and dosage of the drug on a small group of healthy volunteers or patients.

---

[1] Kepplinger EE. *FDA's Expedited Approval Mechanisms for New Drug Products.* Biotechnol Law Rep. 2015 Feb 1;34(1):15-37. doi: 10.1089/blr.2015.9999. PMID: 25713472; PMCID: PMC4326266.Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326266/, Last seen on 11/09/2024

[2] Chawan, Vihang S., Kalpesh V. Gawand, and Abhishek M. Phatak. "Impact of new regulations on clinical trials in India." *Int J Clin Trials* 2.3 (2015): 56-58.Available at https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=7cf7c41fce09ceaf45727993723ae07904945d37, Last seen on 11/09/2024

[3] Kandi, Venkataramana, et al. *"Clinical Trials: The Role of Regulatory Agencies, Pharmacovigilance Laws, Guidelines, Risk Management, Patenting, and Publicizing Results."* Borneo Journal of Pharmacy 6.1 (2023): 93 - 109., APA, Available at https://journal.umpr.ac.id/index.php/bjop/article/view/3263, Last seen on 08/09/2024

Phase II:Evaluates how well the drug works and monitors any side effects in a larger group of patients who have the condition.

Phase III: Confirms the drug's effectiveness and tracks side effects in a large group, often across multiple locations.

India:

CTA: In India, a Clinical Trial Application (CTA) must be submitted to CDSCO before starting a trial. This application includes data from earlier studies, detailed trial protocols, and other necessary documents. CDSCO reviews this to ensure the trial complies with local regulations.

Ethics Committee Review: Like in the U.S., India requires an independent Ethics Committee to review and approve the trial protocol. This committee assesses the ethical aspects of the trial, including how participants are informed and how risks are managed.

Phased Trials: India also follows a phased approach, with Phase IV focusing on monitoring the drug's long-term safety and effectiveness after it has been marketed.

Key Differences:

Review Time:The FDA's process can be faster due to its well-established procedures and resources. In contrast, CDSCO's review might take longer due to procedural differences and resource limitations.

Streamlined Procedures:The FDA offers expedited pathways like Fast Track and Breakthrough Therapy designations to speed up the approval of promising treatments. India is introducing similar initiatives, but the process is still developing.[4]

Ethical Standards and Patient Protection

United States:

Informed Consent: U.S. regulations require that participants fully understand the risks, benefits, and nature of the trial before they agree to participate. This process is closely monitored by IRBs and the OHRP to ensure it meets ethical standards.

Patient Compensation: In the U.S., there are provisions for compensating participants who suffer harm or injury due to the trial. This system addresses and compensates any adverse events that occur.

India:

Informed Consent: India's informed consent process includes extra safeguards, such as video recording, especially for vulnerable populations. This ensures that consent is given freely and with full understanding.[5]

Compensation and Liability: Indian regulations provide specific compensation frameworks for participants who suffer harm or injury during a trial, including compensation for death or permanent injury.

Key Differences:

Documentation: The requirement for video-recorded consent in India highlights its efforts to protect participants, especially in regions with higher illiteracy rates.

Compensation Frameworks: Both countries offer compensation, but India's system is more detailed and prescriptive, reflecting past challenges and aiming to build greater trust among participants

Data Requirements and Documentation

United States:

Preclinical Data: Before a new drug can enter clinical trials in the U.S., the FDA requires a thorough collection of preclinical data. This includes results from animal studies and laboratory tests to demonstrate the drug's safety and potential effectiveness. This stage is crucial for assessing whether the drug is likely to be safe for human use.

Clinical Protocols: The FDA demands detailed clinical trial protocols that describe every aspect of the study. This includes how the study will be conducted, what methods will be used, how risks will be managed, and who the participants will be. The FDA reviews these protocols carefully to ensure they are scientifically sound and that they prioritize participant safety.

---

[4] Mankan, Arun K., et al. *"Cancer Trials Ecosystem in India—Ready for Prime Time?."* JCO Global Oncology 10 (2024): e2300405. Available at https://ascopubs.org/doi/full/10.1200/GO.23.00405, Last seen on 08/09/2024

[5] Roy AM, Mathew A. *Audit of Cancer Clinical Trials in India* . J Glob Oncol. 2019 Jul;5:1. doi: 10.1200/JGO.19.00156.PMID:31283412;PMCID:PMC6690655., available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690655/,Last seen on 09/09/2024

Adverse Event Reporting: During the trial, the FDA requires ongoing reporting of any adverse events—unexpected problems or side effects. Sponsors must report these events in real time, particularly if they are serious, to keep track of the drug's safety and efficacy throughout the study.

India:

Preclinical Data: Similar to the U.S., the CDSCO requires preclinical data for new drugs. This includes animal testing results and lab findings to assess safety and effectiveness. This data helps determine whether the drug is safe to test in humans.

Clinical Trial Protocols: In India, clinical trial protocols must be detailed and include considerations for regional and socioeconomic factors. This is to ensure that trials are not only scientifically rigorous but also appropriate for the diverse population in India.

Adverse Event Reporting: India has specific guidelines for reporting adverse events during clinical trials. Sponsors must follow these guidelines closely to ensure participant safety and compliance with regulations. The reporting requirements are detailed, reflecting the country's commitment to improving safety standards.[6]

Key Differences:

Documentation Detail: Both the U.S. and India require comprehensive documentation, but India's protocols also account for regional and socioeconomic factors. This additional focus reflects the need to tailor trials to India's diverse population and healthcare conditions.

Adverse Event Reporting: While India's adverse event reporting guidelines are improving and increasingly aligning with international standards, they are still developing compared to the more established and faster-paced system in the U.S. This evolution aims to enhance safety monitoring and response in Indian clinical trials.

Challenges in Breast Cancer Clinical Trials

United States:

High Costs and Long Timelines: Clinical trials in the U.S. are known for being very expensive and time-consuming. The high cost includes expenses for recruiting participants, conducting extensive tests, and managing sophisticated technologies. These costs can slow down the process of bringing new treatments to market. Additionally, trials often span several years, which delays the availability of potentially life-saving therapies.

Patient Recruitment: One major challenge is recruiting a diverse range of participants. While efforts are ongoing to improve diversity in clinical trials, there are still significant hurdles. This includes reaching underrepresented populations and ensuring they are well-informed and willing to participate. Despite these challenges, various initiatives aim to enhance participant recruitment and representation.

India:

Infrastructure Limitations: India's clinical trial infrastructure is still developing. Challenges include limited access to cutting-edge technology and facilities, which can impact the quality and speed of research. Additionally, there are logistical issues such as inconsistent access to medical records and varying standards of care across different regions.

Recruitment Issues: Recruiting participants, particularly in rural and remote areas, can be challenging. Many people in these areas have limited access to healthcare services and are

often unaware of clinical trials. This lack of awareness and accessibility makes it harder to find participants and ensure they are well-informed about the trials.

Key Differences:

Infrastructure and Cost: The U.S. has well-established resources and infrastructure for clinical trials, which supports advanced research but comes with high costs. In contrast, trials in India may be more cost-effective due to lower operational expenses, but the infrastructure is still evolving. This can affect the pace and quality of research.

Recruitment and Ethics: Recruitment in India faces greater difficulties due to regional disparities in healthcare access and awareness. Meanwhile, the U.S. is focusing on improving the diversity and inclusiveness of trial participants to better reflect [7]the general population. Both countries are working on their respective challenges, but the nature of these challenges differs based on their healthcare systems and levels of development

---

[6] Anil Babu Payedimarri, Samir Mouhssine, Saleh Aljadeeah, Gianluca Gaidano, Raffaella Ravinetto - *Globalisation of industry-sponsored clinical trials for breast, lung and colon cancer research: trends, threatsand opportunities:* BMJ Oncology 2023;2:e000101.,Available at https://bmjoncology.bmj.com/content/2/1/e000101, Last seen on 09/09/2024

[7] Gao P, Chen J, Hong Z, Choi M, Morgan A, Petushkov A, Lall R, Liu C, Muddu VK, Arroju V, Sunkavalli C, Kim G, Reddy BY. *Landscape of cancer clinical trials in India - a comprehensive analysis of the Clinical TrialRegistry-India.* Lancet Reg Health Southeast Asia. 2023 Nov 10;24:100323. doi: 10.1016/j.lansea.2023.100323PMID: 38756153; PMCID: PMC11096683.,Avaialble at https://pubmed.ncbi.nlm.nih.gov/38756153/ Last seen on 09/09/2024

Recent Regulatory Changes

United States:

Expedited Approval Pathways: The FDA has introduced several programs designed to speed up the approval of new treatments that show promise. These include:

Fast Track Designation: This allows for more frequent communication with the FDA and faster review of data to expedite the development of drugs for serious conditions.

Breakthrough Therapy Designation: Provides more intensive guidance and helps speed up the drug's development and review process if preliminary evidence indicates substantial improvement over existing treatments.

Accelerated Approval: This pathway allows for the approval of drugs based on early evidence of benefit, with the condition that further studies confirm their benefit.These pathways help get potentially life-saving treatments to patients more quickly by reducing bureaucratic delays and focusing resources on high-impact innovations.

Patient-Centric Approaches: The FDA is increasingly incorporating patient feedback into the design and implementation of clinical trials. This includes:

Patient-Reported Outcomes (PROs): Collecting direct feedback from patients about their experiences and quality of life during trials.

Digital Access: Using digital tools and platforms to increase patient participation, such as remote monitoring and telemedicine, making it easier for patients to be involved in trials regardless of their location.

These approaches aim to make trials more relevant to patients' needs and improve their overall experience.

India:

Streamlining Procedures: India has been working on making the clinical trial approval process more efficient and transparent. Recent changes include:

Electronic Submission Systems: Introduction of digital platforms for submitting trial applications and documents, which helps reduce processing time and improves tracking of applications.

Simplified Processes: Efforts to reduce the bureaucratic steps involved in getting approval, making it easier and faster for researchers to start trials.[8]

These changes are intended to make the regulatory process more user-friendly and efficient, facilitating quicker development and availability of new treatments.

Focus on Ethics and Transparency: India is enhancing its focus on ethical standards and transparency in clinical trials. This involves:

Strengthened Ethical Guidelines: Updating and enforcing stricter ethical standards to ensure participant rights and safety are protected.

Transparent Reporting: Improving the transparency of trial results and adverse events to build public trust and ensure accountability.

These measures are aimed at ensuring that trials are conducted ethically and that results are reported transparently.[9]

Key Differences:

Speed of Innovation: The U.S. regulatory system has more established expedited pathways that allow for faster introduction of new treatments. This is due to its more developed infrastructure and resources dedicated to accelerating the drug development process. In contrast, India is working to improve its efficiency, but its processes are still evolving and may not be as fast as those in the U.S.

Digital Integration: The U.S. has a more advanced use of digital tools in clinical trials, including sophisticated remote monitoring and data collection technologies. While India is making strides in digital integration, it still faces challenges such as limited infrastructure and varying levels of technology access across different regions. The ongoing improvements aim to enhance India's capability to leverage digital solutions in clinical trials.

These recent changes reflect both countries' efforts to adapt to new challenges and improve the clinical trial process, but they also highlight the differences in how each country is addressing these challenges.

Conclusion

Understanding the Regulatory Differences:

---

[8] Chakraborty Santam, Mallick Idranil, Luu Hung N, Bhattacharyya Tapesh, Arunsingh Moses, Basu Achari Rimpa, Chatterjee Sanjoy (2021) *Geographic disparities in access to cancer clinical trials in India ecancer* **15** 1161,Available at https://ecancer.org/en/journal/article/1161-geographic-disparities-in-access-to-cancer-clinical- trials-in-india Last seen on 09/09/2024

[9] Saxena, Pikee, and Rohit Saxena. *"Clinical trials: changing regulations in India*." Indian Journal of Community Medicine 39.4 (2014): 197-202.Available at https://journals.lww.com/ijcm/fulltext/2014/39040/Clinical_Trials__Changing_Regulations_in_India.3.aspx Last seen on 11/09/2024

When comparing breast cancer clinical trials in the United States and India, it's clear that each country has its own unique approach shaped by its healthcare priorities and systems.

United States: The U.S. has a well-developed system for managing clinical trials. The FDA uses advanced methods to speed up the approval process for new treatments, such as Fast Track and Breakthrough Therapy designations. These processes help bring new drugs to patients faster. The detailed regulations ensure thorough checks for safety and effectiveness. Plus, using patient feedback and digital tools makes trials more efficient. However, high costs and complex logistics can still be challenges.

India: India is making strides in improving its clinical trial system. The CDSCO is working to simplify approval processes and strengthen ethical standards. New changes, like electronic submissions and updated ethical guidelines, are modernizing the approach. Even with these improvements, there are still hurdles related to infrastructure, recruitment, and procedural efficiency.

What This Means for Stakeholders:

For researchers, doctors, and drug companies involved in breast cancer trials, knowing these regulatory differences is essential. It helps in planning and conducting trials more effectively. Understanding and adapting to these differences can also improve international collaboration and outcomes.

Working Together Globally:

To advance the fight against breast cancer, more global cooperation could be beneficial. By sharing best practices and aligning regulatory standards, countries can streamline processes and speed up the development of new treatments. This teamwork can lead to faster and better treatment options for patients around the world, ultimately improving breast cancer care and outcomes.

BIBLIOGRAPHY

Articles

Kepplinger EE. *FDA's Expedited Approval Mechanisms for New Drug Products.* Biotechnol Law Rep. 2015 Feb 1;34(1):15-37. doi: 10.1089/blr.2015.9999. PMID: 25713472; PMCID: PMC 4326266. Available

at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326266/, Last seen on 11/09/2024

Chawan, Vihang S., Kalpesh V. Gawand, and Abhishek M. Phatak. "Impact of new regulations on clinical trials in India." *Int J Clin Trials* 2.3 (2015): 56-58.Available at https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=7cf7c41fce09ceaf45727993723ae07904945d37,Last seen on 11/09/2024

Kandi, Venkataramana, et al. *"Clinical Trials: The Role of Regulatory Agencies, Pharmacovigilance Laws, Guidelines, Risk Management, Patenting, and Publicizing Results."* Borneo Journal of Pharmacy 6.1 (2023): 93 - 109., APA, Available at https://journal.umpr.ac.id/index.php/bjop/article/view/3263, Last seen on 08/09/2024

Mankan, Arun K., et al. *"Cancer Trials Ecosystem in India—Ready for Prime Time?."*

JCO Global Oncology 10 (2024) :e2300405 Available at https://ascopubs.org/doi/full/10.1200/GO.23.00405, Last seen on 08/09/2024

Roy AM, Mathew A. *Audit of Cancer Clinical Trials in India* . J Glob Oncol. 2019 Jul;5:1. doi: 10.1200/JGO.19.00156.PMID:31283412 ;PMCID:PMC6690655., available at

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690655/ Lastseen on 09/09/2024

Anil Babu Payedimarri, Samir Mouhssine, Saleh Aljadeeah, Gianluca Gaidano, Raffaella Ravinetto - *Globalisation of industry-sponsored clinical trials for breast, lung and colon cancer research: trends, threats and opportunities:* BMJ Oncology 2023;2:e000101.,Available at

https://bmjoncology.bmj.com/content/2/1/e000101, Last seen on 09/09/2024

Gao P, Chen J, Hong Z, Choi M, Morgan A, Petushkov A, Lall R, Liu C, Muddu VK, Arroju V, Sunkavalli C, Kim G, Reddy BY. *Landscape of cancer clinical trials in India - a comprehensive analysis of the Clinical Trial Registry-India.* Lancet Reg Health Southeast Asia. 2023 Nov 10;24:100323. doi: 10.1016/j.lansea.2023.100323. PMID: 38756153; PMCID: PMC11096683.,Avaialble at https://pubmed.ncbi.nlm.nih.gov/38756153/ Last seen on 09/09/2024

Chakraborty Santam, Mallick Idranil, Luu Hung N, Bhattacharyya Tapesh, Arunsingh Moses, Basu Achari Rimpa, Chatterjee Sanjoy (2021) *Geographic disparities in access to cancer clinical trials in India ecancer* **15** 1161,Available at https://ecancer.org/en/journal/article/1161-geographic-disparities-in-access-to-cancer-clinical- trials-in-india Last seen on 09/09/2024

Saxena, Pikee, and Rohit Saxena. *"Clinical trials: changing regulations in India*." Indian Journal of Community Medicine 39.4 (2014): 197-202.Available at https://journals.lww.com/ijcm/fulltext/2014/39040/Clinical_Trials__Changing_Regulations_in_India.3.aspx Last seen on 11/09/2024